69 autonomous agents across 5 tiers. 167 API endpoints. 300 diseases. Patient-specific generative therapeutics. From a disease name or a patient genomic profile to safety-screened, IP-cleared therapeutic candidates in hours.
Each stage requires a StageDecisionRecord before advancement. No candidate advances without passing every kill condition. The governance trail is immutable.
Every layer produces real computation, real data, and real audit records.
StageDecisionRecords, audit trails, kill switches, AIDD-GOV compliance, GOV-FM self-improving scorer. Every decision immutable.
AutoDock Vina 1.2.7 real docking, RDKit ADMET, BRICS retrosynthesis, 3D conformers, 72-rule toxicity SMARTS, patent search.
Orphanet, GARD, ClinVar, HPO queried in parallel. Population-level epidemiological data grounding every campaign.
ASKCOS retrosynthesis with BRICS fallback, commercial availability, CRO brief generator, assay protocol library.
Genotype-to-compound matching, population estimation (gnomAD + Orphanet), companion diagnostics, foundation data.
OpenMM MD simulation, FEP binding affinity (ΔΔG), system preparation, GPU detection, trajectory analysis (RMSD/RMSF).
TPP+ conjugate design (850x matrix accumulation), 7-strategy prodrug designer, 5-route formulation spec, CMC parameters.
Pre-IND meeting packages, CMC dossier sections, nonclinical summaries, full IND assembly (CTD Modules 1-5), FDA readiness scoring.
OpenTargets GraphQL, ChEMBL, FDA FAERS, ClinicalTrials.gov, AlphaFold, UniProt, STRING DB, NCBI Entrez. Live data feeds.
Upload tumor genomics, RNA sequencing, or clinical lab reports. The platform infers the patient's disease-specific regulatory circuitry, simulates interventions, and generates multi-modal therapeutic candidates, all under governed audit.
Academic researchers, thesis work, non-commercial use. Full governed pipeline. Apply for beta access.
Clinicians, genomics programs, oncology centers. Patient data upload, regulatory graph inference, multi-modal candidates.
Biotech startups, drug discovery labs, CROs. Unlimited campaigns, antibody design, API access, CRO dispatch.
Pharma, large biotechs, hospital networks. Private deployment, multi-user, SLA, custom disease domains, white label.
All tiers include full governance audit trail. Patent Pending. Contact jyborges@bu.edu for Enterprise pricing.
Every manuscript passed R1 revision, R2 independent review, and IP audit. Preprint versions redacted per patent security protocol.
M01-M10 on SSRN. Pathway mapping, compound design, docking, ADMET, RL optimization, platform architecture.
5 ChemRxiv LIVE. Research Square DOI 10.21203/rs.3.rs-9305508/v1. SSRN 10/10. arXiv pending endorsement.
Apache 2.0. 10 schemas, 3 conformance levels. github.com/fxmedus/aidd-gov
Filed March 27, 2026. Two amendments, 51 pages. Covers 69-agent 5-tier architecture, Phases A-E, SIRLP, AIDD-GOV, patient-specific generative therapeutics.
25 gene targets. 163 candidates per campaign. 14 patient variants. 54,204 patients globally. Diseases with zero approved treatments.
"The platform addresses 14 variant populations representing 54,204 patients globally. For PINK1 G309D alone, 847 patients are eligible for candidate ACTIVATOR compounds. A targeted PCR diagnostic panel identifies eligible patients at low per-test cost."
Auto-generated by /api/patient/foundation-data — real numbers, real computationUpload patient molecular data. The platform infers disease regulatory circuitry, simulates interventions, and generates optimised candidates across small molecules, peptides, and antibodies.
Patient-specific therapeutic reports. CRO-ready dispatch packages. Governance audit trails. Foundation proposals with real patient numbers. If you run a precision oncology program, genomics center, or rare disease foundation, we want to hear from you.